Differences in treatment effect size between progression-free survival and overall survival in anti-PD-1/PD-L1 inhibitors-based trials in advanced NSCLC: a systematic review and meta-analysis.

ABSTRACT:

Background

To investigate the differences in treatment effect sizes between progression-free survival (PFS) and overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with programmed cell death 1 (PD-1) and its ligand (PD-L1) blockade-based treatments.

Methods

The differences in treatment effect sizes between PFS and OS were assessed by using a ratio of hazard ratio (rHR): the HR for PFS to that for OS. A random effects meta-analysis across trials was conducted to generate the combined rHR. We also evaluated the feasibility of adopting PFS as the surrogate of OS by using Spearman correlation coefficient (R) between logHR_PFS and logHR_OS.

Results

A total of 27 randomized controlled trials (RCTs) with 15,590 patients wer

SUBMITTER: Zhou Z 

PROVIDER: S-EPMC8264319 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature